A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

开始日期2026-12-01

申办/合作机构

思路迪科技（上海）有限公司

ChiCTR2600119589

/ SuspendedN/AIIT

A randomized, open label, controlled multicenter clinical study comparing the safety and efficacy of hydromorphone sustained-release tablets and hydrocodone sustained-release tablets in the treatment of elderly cancer pain patients in China

开始日期2026-06-01

申办/合作机构

浙江省肿瘤医院

ChiCTR2600125700

/ Not yet recruitingN/AIIT

A Comparative Study on the Application of Hydrocodone Extended-release Tablets and Oxycodone Extended-release Tablets in the Management of Cancer Pain in Patients with Primary Liver Cancer

开始日期2026-05-19

申办/合作机构-

100 项与盐酸羟考酮相关的临床结果

登录后查看更多信息

100 项与盐酸羟考酮相关的转化医学

登录后查看更多信息

100 项与盐酸羟考酮相关的专利（医药）

登录后查看更多信息

2,044

项与盐酸羟考酮相关的文献（医药）

2026-05-01·NEUROTOXICOLOGY AND TERATOLOGY

Postnatal environment differentially modulates neurodevelopmental outcomes following voluntary prenatal oxycodone exposure in rats

Article

作者: Isgate, Sara B ; Cunningham, Cora C ; Gulsby, Megan ; Gildawie, Kelsea R ; Celatka, Jillian ; Budge, Kerri E ; Vassoler, Fair M ; Byrnes, Elizabeth M

As prenatal opioid exposure becomes increasingly prevalent, understanding which neurodevelopmental effects are amenable to postnatal intervention has become a critical question. Clinically, prenatal exposure and maternal factors that affect offspring development often co-occur, making it difficult to determine which developmental outcomes are directly attributable to drug effects versus postnatal environmental influences. Preclinical models can be useful in disentangling these interacting factors. Using a rat model of voluntary maternal Oxycodone (Oxy) self-administration, we examined whether postnatal rearing environment could ameliorate neonatal opioid withdrawal syndrome (NOWS)-like symptoms. Cross-fostering separated prenatal drug effects from postnatal rearing and revealed differential sensitivity to environmental modification. Altered ultrasonic vocalizations were rescued when Oxy-exposed offspring were reared by drug-naïve dams, while increased motor activity persisted regardless of rearing condition. Oxy-exposed offspring reared by Oxy-exposed dams showed a distinct developmental trajectory characterized by increased vocal power and reduced frequency variability. These early alterations persisted across the postnatal period. Unexpectedly, maternal opioid intake levels during pregnancy did not predict NOWS-like symptom severity. However, early vocalization patterns did show group-specific predictive relationships with adult markers (plasma corticosterone and nucleus accumbens MeCP2 expression), suggesting potential continuity between early behavioral alterations and later physiological changes. The functional significance of these relationships requires further investigation. Overall, some, but not all, developmental effects of prenatal opioid exposure could be ameliorated by the postnatal rearing environment. These findings suggest that early behavioral profiles may help identify offspring at greatest risk for persistent developmental alterations, highlighting the potential value of early assessment and postnatal intervention.

2026-05-01·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The influence of UV filters (Oxybenzone and Avobenzone) on lipid monolayers, with consideration of the role of lipid structure and monolayer composition

Article

作者: Wyżga, Beata ; Olechowska, Karolina ; Skóra, Magdalena ; Hąc-Wydro, Katarzyna

The widespread use of UV filters and their release into the environment raise concerns due to their potential harmful effects on living organisms. Consequently, the toxicity and bioaccumulation capacity of UV filters are currently the subject of an intensive study. This work investigates the effect of two UV filters, Oxybenzone (Oxy) and Avobenzone (Avo), on the monolayers formed by the lipids typical for bacteria membranes, as well as on the mixed lipid films imitating E. coli and S. aureus membranes. The studied lipids differed in their hydrophobic and hydrophilic parts, enabling discussion of the effect of lipid structure and monolayer composition on UV filter affinity for the model systems. The experiments involved surface pressure/area measurements, penetration studies, and Brewster angle microscopy investigations. The in vitro tests on various bacteria strains were also performed. The studied UV filters showed varying affinity for the lipids and membrane models tested. Avo modified the properties of the investigated systems more strongly than Oxy. However, the most important conclusion was that filters' affinity for lipid systems depended on both the structure of the lipids, which determines monolayer properties, and the monolayer's organization. The presence of condensed domains dispersed in a more fluid matrix was a particularly important factor in enhancing the incorporation of Avo and its fluidizing effect. The toxic effects of Avo and Oxy were not directly linked to their interactions with lipids. Nevertheless, the affinity of these compounds for lipids and membrane domains may facilitate their accumulation in the cells of living organisms.

2026-05-01·JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Pre-emptive Oxycodone versus Sufentanil for Acute and Delayed Pain after Transcatheter Arterial Chemoembolization: A Randomized Controlled Trial with Inflammatory Biomarker Analysis

Article

作者: Chen, Yu ; Zu, Qing-Quan ; Zhou, Wei-Zhong ; Xu, Bo-Jing ; Wu, Wen-Tao ; Liu, Sheng ; Shi, Hai-Bin ; Hang, Yu ; Li, Bing

PURPOSE:

To compare the effectiveness of pre-emptive oxycodone versus sufentanil for acute and delayed pain control after transcatheter arterial chemoembolization (TACE).

MATERIALS AND METHODS:

In this prospective, double-blind trial, 40 patients scheduled for TACE were randomized to receive intravenous oxycodone (0.1 mg/kg) or sufentanil (0.1 μg/kg) 15 minutes before TACE. Pain intensity was assessed using a visual analog scale (VAS) during acute (0-24 hours) and delayed (Days 2-7) phases. Inflammatory biomarkers (white blood cell count, neutrophil percentage, C-reactive protein, and interleukin [IL]-6) were measured at baseline and 24 hours after TACE. The primary outcome was the highest acute-phase VAS scores; secondary outcomes included delayed-phase pain, changes in inflammatory biomarkers, and adverse events.

RESULTS:

Oxycodone demonstrated superior analgesia, with lower intraprocedural VAS scores (median, 0 [interquartile range {IQR}, 0-1.0] vs 3.5 [IQR, 1.3-4.8]; P < .001) and reduced incidence of moderate-to-severe pain (5% vs 50%; P = .003). This benefit persisted at 1-6 hours after TACE (median, 0 [IQR, 0-1.0] vs 2 [IQR, 0-3.0]; P = .042). During the delayed phase, oxycodone maintained lower pain scores (median, 0 [IQR, 0-0] vs 0 [IQR, 0-3.8]; P = .042) and fewer episodes of moderate pain (0% vs 25%; P = .047). IL-6 elevation was greater in patients developing delayed pain (671.16% vs 135.97% increase; P = .030). Adverse event rates were comparable.

CONCLUSIONS:

Pre-emptive oxycodone provided more effective acute and delayed pain control after TACE compared with sufentanil, with comparable safety. The association between IL-6 elevation and delayed pain suggests an inflammatory pain component, supporting further investigation of combined opioid and anti-inflammatory strategies.

392

项与盐酸羟考酮相关的新闻（医药）

2026-05-28

·ir.tonixpharma.com

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia Data demonstrate a substantial and persistent health burden associated with prescribed opioid use among adults with fibromyalgia Tonix commercially launched TONMYA® in November 2025, the first new fibromyalgia drug for adults in the U.S. in over 15 years approved by the U.S. Food and Drug Administration (FDA) BERKELEY HEIGHTS, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, presented data from a real-world claims analysis of opioid use in U.S. adults with fibromyalgia at the 2026 ASCP Annual Meeting, held May 26-29, 2026, in Miami Beach, Florida. “Opioids remain widely prescribed for fibromyalgia despite long-standing guidelines that discourage their use due to lack of efficacy, a growing concern that they worsen fibromyalgia symptoms and the risk of dependence,1-6” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “The discrepancy between real-world practice and evidence-based recommendations reveals a gap in knowledge and an urgent need to educate health care prescribers about the nature of fibromyalgia and the availability of non-opioid, FDA-approved medicines. Tonix is currently executing on the launch of TONMYA® (cyclobenzaprine HCl sublingual tablets), a first-in-class, first-line, non-opioid analgesic medicine FDA approved for daily bedtime administration and long-term use in adults with fibromyalgia.” Data presented at ASCP 2026 represent a retrospective cohort study using the Symphony Health closed claims database, encompassing administrative medical and pharmacy claims collected between April 2021 and April 2024, to evaluate opioid and benzodiazepine use among adults diagnosed with fibromyalgia (ICD-10-CM diagnosis code M79.7). The study’s objective was to quantify opioid and benzodiazepine use in patients diagnosed with fibromyalgia and characterize patients by age, insurance coverage, and polypharmacy. The Year 3 cohort (April 2023 to March 2024) included 261,776 adult patients, with a mean age of 52.3 years. The cohort was predominantly female (92.1%). Among patients with Commercial or Medicare Advantage insurance, 40.2% of patients were prescribed at least one opioid, with most claims for tramadol (13.7%), followed by oxycodone (13.1%). Among Medicaid patients, 38.8% were prescribed at least one opioid, with most claims for oxycodone (15.7%), followed by tramadol (11.1%). The Medication Possession Ratio (MPR) for opioid use was similar for Commercial or Medicare Advantage patients (0.39) and Medicaid patients (0.40). Opioid use showed the highest prevalence in older age groups: 61-65 years (43.1%), 66-70 years (39.2%), 71-75 years (38.5%), and >75 years (34.4%), and was lower, but still common for younger adults 18-25 years (20.9%). Concomitant opioid and benzodiazepine use was similar in patients covered under Medicare Advantage or Commercial insurance (19.1%) and Medicaid patients (20.4%). A copy of the Company’s poster presentation, "Opioid Use in Patients with Fibromyalgia: A Retrospective Claims Analysis," is available under the Scientific Presentations tab on the Tonix website at https://www.tonixpharma.com/scientific-presentations/. About Fibromyalgia Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts more than 10 million adults in the U.S., predominantly in women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products. About TONMYA® (cyclobenzaprine HCl sublingual tablets) TONMYA (cyclobenzaprine HCl sublingual tablets) is a sublingual tablet formulation of cyclobenzaprine hydrochloride that was approved on August 15, 2025, by the FDA for the treatment of fibromyalgia in adults. TONMYA is the first new prescription medicine approved for fibromyalgia in more than 15 years. TONMYA provides rapid transmucosal absorption of cyclobenzaprine and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypassing first-pass hepatic metabolism. TONMYA is a multifunctional agent with potent binding and antagonist activities at the 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors. TONMYA was investigated as TNX-102 SL. TNX-102 SL is also being developed to treat acute stress disorder (ASD)/acute stress reaction (ASR), and major depressive disorder (MDD). The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10,357,465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix’s proprietary TONMYA composition. These patents are expected to provide TONMYA with U.S. market exclusivity until 2034. Citations 1Winslow BT, et al. Am Fam Physician. 2023;107(2):137–44. 2Macfarlane GJ, et al. Annals of the Rheumatic Diseases. 2017;76(2):318. 3Martucci KT, et al. Sci Rep. 2019;9(1):9633. 4Turner JA, et al. Pain. 2016;157(10):2208–2216. 5Fitzcharles MA, et al. J Rheumatol. 2013;40(8):1388–1393. 6American College of Rheumatology. Fibromyalgia. 2024. Available from: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Fibromyalgia. Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases where there exists high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science behind TONMYA in Phase 2 clinical studies to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody TNX-4800 (anti-OspA mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com. *Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contacts Jessica Morris Tonix Pharmaceuticals investor.relations@tonixpharma.com (862) 799-8599 Brian Korb astr partners (917) 653-5122 brian.korb@astrpartners.com Media Contacts Deborah Elson Tonix Pharmaceuticals deborah.elson@tonixpharma.com Ray Jordan Putnam Insights ray@putnaminsights.com INDICATION TONMYA is indicated for the treatment of fibromyalgia in adults. CONTRAINDICATIONS TONMYA is contraindicated: In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected. With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs. During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. In patients with hyperthyroidism. WARNINGS AND PRECAUTIONS Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy. Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases. Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures. Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs. CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities. Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer. DRUG INTERACTIONS MAO inhibitors: Life-threatening interactions may occur. Other serotonergic drugs: Serotonin syndrome has been reported. CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced. Tramadol: Seizure risk may be enhanced. Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED). Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition. Pediatric use: The safety and effectiveness of TONMYA have not been established. Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions. Please see additional safety information in the full Prescribing Information. To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Released May 28, 2026

上市批准临床结果临床2期ASCO会议

2026-05-27

·PRNewswire

End Kratom Addiction Announces Virginia Governor Signing in New Law Banning 7-OH and Rejecting Kratom's "Harmless" Narrative with Mandatory Addiction Warnings

RICHMOND, Va., May 27, 2026 /PRNewswire/ -- The new law is considered a major victory that will protect thousands of Virginia families by exposing the truth about kratom and its devastating effects, including addiction, seizures, psychosis, liver damage, and in some cases, death. It is also viewed as a significant defeat for the American Kratom Association, the industry's lobbying arm based in Gainesville VA, which has spent years portraying kratom as a safe, natural wellness product. Continue Reading From left to right: Cameron Francis, Dean Francis, VA Gov. Spanberger, VA Del. Joshua Cole, & Chief of Staff to Del. Joshua Cole, Eric Sundberg. A celebratory signing ceremony with Governor Spanberger took place on May 26, 2026, alongside Cameron Francis, who nearly died and lost most of his twenties after becoming addicted to kratom in 2017 while competing as a track athlete at Liberty University. At the time, Cameron was close to breaking the four-minute mile before his life spiraled into addiction. Cameron was joined by his father, Dean Francis, founder of End Kratom Addiction in 2025, and Delegate Josh Cole, who sponsored the legislation. Effective July 1, 2026, kratom products in Virginia must be kept in locked cases or behind the counter and carry the following warning label: "THIS PRODUCT MAY CAUSE DEPENDENCE AND OPIOID-LIKE WITHDRAWAL." Additionally, highly potent 7-hydroxymitragynine (7-OH) products may no longer be sold. 7-OH is an opioid produced naturally in the body after kratom consumption and is widely accepted to be stronger than morphine. It is largely responsible for kratom's euphoric and pain-relieving effects, and consequently, the risk of addiction and other serious health consequences. In recent years, some manufacturers learned how to bypass the body's natural conversion process through oxidation and sell 7-OH directly as a concentrated tablet. While the tablet unleashed another wave of addiction and harm, it also exposed the fundamental truth the industry had hidden for many years: kratom naturally converts in the body into 7-OH. During a committee hearing, State Senator Jeremy McPike repeatedly pressed an American Kratom Association expert with a simple question: "What does kratom turn into in the liver?" After asking the question three times, the expert finally acknowledged that kratom converts into 7-hydroxymitragynine (7-OH). It was later revealed that the same expert had previously testified on behalf of Purdue Pharma regarding OxyContin in 2004. "This law is a victory for truth over deception," said Dean Francis. "Virginia lawmakers rejected the false "non-addictive, harmless" narrative of the American Kratom Association and its so-called experts, as they discovered the industry's trade secret: part of kratom converts in the body to an opioid stronger than morphine." The bill itself - HB360 - received broad support from across Virginia's business, medical, and addiction treatment communities. Supporters included the Virginia Pharmacy Association, the Virginia Society of Health System Pharmacists, Chamber RVA, the Virginia Black Chamber of Commerce, the Virginia Hispanic Chamber of Commerce, the Metropolitan Business League, the Southern Virginia Chamber of Commerce. Many addiction treatment professionals delivered blunt, compelling testimony in committee hearings, stating kratom withdrawal is often as bad—or worse—than heroin. One clinical director used the word "demonic" to describe the kratom withdrawal she sees regularly. She added, "If any of you doubt what I'm saying, please come visit us for just one day." Kate Gibson, a psychiatric nurse practitioner who works at the Coleman Clinic in Richmond, testified that over 50% of the patients being presented to her are for kratom addiction, and that kratom requires the same medical protocol as heroin. Delegate Josh Cole, who sponsored the legislation, spoke about both the immediate impact of the law and the broader message it sends for the future: "I believe we sent a clear message: Virginians deserve the truth about kratom. Marketing an opioid-like substance as a harmless wellness supplement is unacceptable, especially when young people, families, and vulnerable consumers may not understand the high-stake risks. This bill does something critical: it cuts through the smoke and mirrors around kratom and makes clear that this substance can act like an opioid. If this law helps even one person understand how risky kratom can be, and how addictive it can become, then I believe we have done the right thing. This is about protecting people from addiction they never saw coming, and The bill advanced through with overwhelming bipartisan margins at every stage of the legislative process, including 7-3, 21-1, and 15-0 in committee, and 95-2 and 40-0 on the floor. "These were not narrow votes. They represent a resounding bi-partisan rebuke," said Hilary Tesluck, Executive Director of End Kratom Addiction. "Virginia chose families over lobbyists, facts over fiction, and public health over predatory commerce. Industry spin is not science and paid testimony is not truth." "The message to the American Kratom Association and its members is simple," Francis said. "Your playbook of deception was exposed. Your narrative was rejected. The truth has been revealed." Media Contact: Hilary Tesluck | Executive Director, End Kratom Addiction | Email: [email protected] SOURCE End Kratom Addiction 21% more press release views with Request a Demo

2026-05-26

·搜狐新闻

信息服务 | 重医SCI周报（2026年第13期）

2026年第13期SCI周报本周SCI数据库共收录113篇以重医为单位发表的论文，其中以第一单位或通讯单位发文79篇，涵盖临床医学、基础医学、药学、公共卫生、护理学等多个学科领域。论文发表期刊包括《新英格兰医学杂志》《JAMA内科学》等顶级期刊，以及《化学工程杂志》《核酸研究》等高影响力期刊，整体以Q1区论文为主。发文热点集中在心血管疾病、肿瘤、代谢性疾病、神经科学、感染免疫、药物研发、医学影像等研究领域。第1条，共79条标题: Physiologic Pacing in Heart Failure- TO THE EDITOR期刊: NEW ENGLAND JOURNAL OF MEDICINE作者: Xiong, BQ; Wu, Q; Qu, GS通讯作者: Qu, GS (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China.文献类型: Letter影响因子: 78.5, JCR分区: Q1, 中信所分区: Q1学院: 附二院; 附二院第2条，共79条标题: Understanding Weight Regain After Tirzepatide Withdrawal期刊: JAMA INTERNAL MEDICINE作者: Chuan, F; Gao, YY; Zhou, B通讯作者: Zhou, B (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, 1 Youyi Rd, Chongqing, Peoples R China.文献类型: Letter; Early Access影响因子: 23.3, JCR分区: Q1, 中信所分区: Q1学院: 附一院第3条，共79条标题: FABRY CARDIOMYOPATHY PRESENTING AS HYPERTROPHIC PHENOTYPE WITH LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION: A CASE SERIES期刊: JACC-JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY作者: Huang, B;Li, YZ;Chen, J; et al.文献类型: Meeting Abstract影响因子: 22.3, JCR分区: Q1, 中信所分区: Q1学院: 附一院第4条，共79条标题: Computational discovery of nutritional peptides targeting KEAP1-NRF2 signaling: A novel in-silico strategy to mitigate oxidative stress期刊: TRENDS IN FOOD SCIENCE & TECHNOLOGY作者: Asghar, MA;Zhang, LF;Cai, JH; et al.通讯作者: Zhang, X; Zhao, QJ (通讯作者)，Chongqing Med Univ, Coll Pharm, Chongqing, Peoples R China.文献类型: Article影响因子: 15.4, JCR分区: Q1, 中信所分区: Q1学院: 药学院; 药学院摘要：背景：氧化应激是心血管疾病、糖尿病、代谢功能障碍、神经退行性病变及衰老相关衰退等慢性疾病的主要驱动因素。转录因子NRF2是抗氧化防御的核心调控因子，控制着细胞保护和解毒通路。新出现的证据表明，食物来源的肽可以作为KEAP1-NRF2轴的天然调节剂，提供了一类在氧化还原调节和健康衰老中具有潜在作用的新型分子。范围与方法：本综述整合了近期在不同膳食来源中鉴定抗氧化肽的研究进展。利用计算预测工具、分子对接、序列分析和网络药理学，我们评估了肽的生物活性、KEAP1结合潜力及通路水平的相关性。同时强调了该领域的趋势，包括鱼类和海鲜蛋白质的普遍性以及植物来源肽日益增长的贡献，以反映营养保健品领域不断发展的兴趣。主要发现与结论：短小、疏水且富含芳香族氨基酸的肽基序，如WPWR和FPFPR，表现出较强的预测生物活性和非共价KEAP1亲和力。部分序列含有富含亮氨酸的模式，可能模拟NRF2的ETGE基序，提示其具有破坏KEAP1-NRF2相互作用的机制。蛋白质-蛋白质相互作用和富集分析进一步将肽靶点与NRF2调控的基因以及关键通路联系起来，支持其多功能的抗氧化和抗炎作用。临床前和早期临床研究还表明其具有抗糖尿病、抗高血压、神经保护和抗衰老等额外益处。尽管存在生物利用度低、稳定性问题、缺乏NRF2特异性检测方法以及监管不确定性等挑战，食物来源的肽作为氧化应激的分子调节剂仍显示出巨大潜力。整合计算与机制研究的策略可能指导基于肽的干预措施的开发，以延长健康寿命并减轻年龄相关疾病。扫码获取全文第5条，共79条标题: A magnetic field-assisted DNA nanoflower-based strategy for efficient detection of dual surface proteins on extracellular vesicles期刊: CHEMICAL ENGINEERING JOURNAL作者: Liu, XX;Bai, HJ;Wu, X; et al.文献类型: Article影响因子: 13.2, JCR分区: Q1, 中信所分区: Q1学院: 妇幼保健院扫码获取全文第6条，共79条标题: Disulfiram-loaded small molecule prodrug co-assembled nanoparticles for targeted inhibition of macrophage pyroptosis in effective atherosclerosis therapy期刊: CHEMICAL ENGINEERING JOURNAL作者: Zhang, YX;Bai, YY;Zeng, JY; et al.文献类型: Article影响因子: 13.2, JCR分区: Q1, 中信所分区: Q1学院: 基础医学院; 基础医学院摘要：动脉粥样硬化是一种慢性炎症性血管疾病，是缺血性心脑血管疾病的主要原因。动脉粥样硬化病变部位的巨噬细胞焦亡是AS进展和加重的重要驱动因素。因此，靶向抑制AS病变中的巨噬细胞焦亡是一种理想的治疗策略。在此，我们合成了一种活性氧响应的普罗布考-艾地苯醌异源二聚体小分子前药，并将其与焦亡抑制剂双硫仑共组装，形成小分子前药共组装纳米粒。为了增强对动脉粥样硬化斑块内巨噬细胞的靶向性，在PIDNPs表面引入了甘露糖修饰。所得的甘露糖修饰的PIDNPs能够有效靶向AS病变中的巨噬细胞，并响应细胞内高ROS水平释放Pu、ID和DSF。Pu和ID有效抑制了细胞内ROS的产生，从而与DSF协同抑制巨噬细胞焦亡，实现高效且安全的AS治疗。我们的研究表明，MPIDNPs促进了炎症血管内皮细胞的摄取并增强了跨内皮转运。此外，MPIDNPs在体外能有效抑制巨噬细胞的氧化应激和焦亡。在AS小鼠模型中，MPIDNPs表现出安全有效的抗AS治疗效果。本研究开发了一种用于靶向抑制AS病变中巨噬细胞焦亡的新型纳米制剂。扫码获取全文第7条，共79条标题: A universal and orthogonal safety valve for CRISPR/Cas12a without chemical modification or external stimulation期刊: NUCLEIC ACIDS RESEARCH作者: Luo, W;Wu, Y;Ni, DS; et al.文献类型: Article影响因子: 13.1, JCR分区: Q1, 中信所分区: Q1学院: 附二院; 附二院, 检验医学院摘要：基于CRISPR/Cas的基因编辑技术在过去十年中取得了显著进展，但其广泛的实际应用仍受到安全性问题的限制。尽管在CRISPR/Cas激活之前或期间应用的调控策略已大幅提高了序列、时间和空间特异性，但已激活的Cas核酸酶的持续活性仍可能增加不可控编辑的风险。因此，迫切需要一种有效的激活后控制策略。在此，我们报道了一种无需修饰和刺激的RNA抑制剂，它作为CRISPR/Cas12a的激活后安全阀。通过利用Cas12a的别构敏感性以及核酸链置换的热力学和动力学可编程性，iRNA驱动已激活的Cas12a核糖核蛋白回到非活性状态，在已验证的Cas12a框架内实现了通用的、序列可编程的正交激活后抑制。实验和模拟阐明了iRNA介导的链置换的机制基础，并证明了其高抑制效率、可逆循环控制、兼容性、可扩展性、正交性和通用性。重要的是，iRNA在细胞中还作为一种可编程、自主运行的安全阀，在抑制不可控编辑的同时保留了PCSK9基因敲除功能。iRNA凭借其设计简单、优异的生物相容性和自主细胞内表达，为下一代可调控CRISPR系统奠定了基础，并在精准治疗、细胞治疗和分子诊断中具有广泛潜力。原文第8条，共79条标题: An oral nanocombinatorial agent exhibits pleiotropic improvement in diabetic nephropathy via modulation of the SCAP/SREBPs pathway期刊: JOURNAL OF NANOBIOTECHNOLOGY作者: Su, Y;Wen, HB;Hu, K; et al.文献类型: Article影响因子: 12.6, JCR分区: Q1, 中信所分区: Q1学院: 附属儿童医院; 附属儿童医院, 附二院摘要：糖尿病肾病的多因素发病机制和多细胞参与特性，与传统的单靶点治疗策略的不足形成了鲜明对比。这种差异凸显了对具有全面靶向能力的新型药物的迫切需求。在此，我们确定SCAP/SREBPs通路是DN的核心驱动因素，其在关键肾实质细胞中的激活促进了脂质代谢紊乱和炎症，从而加剧了肾损伤。在这一发现的指导下，我们筛选了一个由SCAP抑制剂与壳聚糖自组装构成的含245种成员的纳米颗粒库，并确定壳聚糖-盐酸石蒜碱纳米粒为最佳候选药物。由于其高效的肠道吸收和在系膜细胞及近端肾小管上皮细胞中的显著蓄积，口服CLNPs通过对抗脂质积聚和炎症，在DN小鼠模型中强效减轻了肾损伤，这与SCAP/SREBPs通路抑制的结果一致。至关重要的是，CLNPs预防了游离石蒜碱的肝毒性，从而降低了死亡率并实现了更安全的长期治疗。总之，我们的研究结果证明了CLNPs治疗DN的可行性，从而为通过一种能够对抗多种共存病理损伤的单一组合药物来对抗复杂疾病提供了一种可推广的策略。原文第9条，共79条标题: Fecal microbiota transplantation and Akkermansia muciniphila restore neurodevelopment and behavior via the gut-brain axis in autism-like zebrafish期刊: ISME JOURNAL作者: Jia, PP;Li, Y;Yang, HY; et al.文献类型: Article影响因子: 10, JCR分区: Q1, 中信所分区: Q1学院: 公卫学院; 公卫学院摘要：目前针对自闭症谱系障碍的有效疗法十分有限，且肠道微生物群与大脑发育之间的功能联系尚未完全阐明。本研究以Katnal2突变体斑马鱼作为ASD样模型，评估了来自野生型供体的粪便微生物群移植或补充嗜黏蛋白阿克曼菌是否能改善神经发育缺陷。评估内容包括常规饲养和无菌饲养鱼类的发育表型、行为、微生物谱、神经递质相关基因表达以及短链脂肪酸信号传导。野生型供体的FMT和补充A. muciniphila显著改善了Katnal2突变体的孵化率、生长参数、心率和运动能力，而来自Katnal2突变体的微生物群则在野生型受体中诱导了类似的缺陷。A. muciniphila成功定植于肠道，重塑了微生物群落，并减少了焦虑样行为。机制上，A. muciniphila上调了参与多巴胺、血清素和γ-氨基丁酸合成的基因，下调了血清素受体htr3a，并增强了SCFA受体ffar2的表达，且这一过程与总SCFA水平无关。相关性分析以样本特异性的方式将关键发育、行为和转录变化与改变的微生物属联系起来，突出了遗传和益生菌干预中由组成驱动的神经调节效应。因此，以A. muciniphila为靶向的微生物群干预通过重塑肠-脑轴挽救了ASD模型中的神经发育损伤，支持其转化潜力。原文第10条，共79条标题: Sequential treatment of infectious bone defects with three dimensional-printed body temperature-responsive shape memory scaffold coated with metal-polyphenol layers期刊: BURNS & TRAUMA作者: Yang, SH;Hu, QS;Hu, YK; et al.文献类型: Article影响因子: 9.6, JCR分区: Q1, 中信所分区: Q1学院: 附一院; 附一院摘要：背景：感染性骨缺损以持续的细菌侵袭和免疫微环境失衡为特征，这显著阻碍了骨再生。近年来，已有许多骨修复材料被开发出来以应对感染性骨缺损相关的复杂病理微环境。然而，感染清创后缺损尺寸的动态变化对实现人工骨移植物有效的骨整合构成了重大挑战。因此，需要开发一种兼具抗菌、免疫调节和成骨性能的集成支架，以实现不规则骨缺损的填充。方法：采用低温打印结合冷冻干燥技术，将左旋聚乳酸-三亚甲基碳酸酯与柠檬酸改性羟基磷灰石复合，制备了具有仿生松质骨多孔结构的形状记忆支架。通过“贻贝”效应在支架表面进一步包被金属多酚网络单宁酸-镁涂层，以实现对感染性骨缺损的序贯治疗。结果：该支架在生理温度下能与缺损界面自适应整合，实现了优异的骨整合性能。柠檬酸改性羟基磷灰石的加入有效优化了聚合物-无机相打印墨水体系，显著增强了支架的机械强度和矿化能力。同时，外层的TA-Mg金属多酚涂层在体外和体内均表现出优异的病原体清除性能。它还通过影响巨噬细胞极化来调节免疫微环境，最终促进感染性骨缺损的骨再生。结论：PT/CHA@TA-Mg支架通过自适应填充实现骨整合，并通过抗菌、免疫调节和成骨分化实现对感染性骨缺损的多阶段治疗。原文第11条，共79条标题: Spermidine alleviates sepsis-induced cardiomyopathy by improving mitochondrial quality and quantity via a Metallothionein 1-dependent antioxidant pathway期刊: PHYTOMEDICINE作者: Long, SY;Sun, JX;Wu, YG; et al.文献类型: Article影响因子: 8.3, JCR分区: Q1, 中信所分区: Q1学院: 附二院; 附二院原文第12条，共79条标题: Enzyme-converted O kidneys allow ABO-incompatible transplantation without hyperacute rejection in a human decedent model期刊: AMERICAN JOURNAL OF TRANSPLANTATION作者: Zeng, J;Ma, M;Tao, Z; et al.通讯作者: Lin, T; Song, TR (通讯作者)，Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China.; Lin, T; Song, TR (通讯作者)，Sichuan Univ, West China Hosp, Kidney Transplantat Ctr, Chengdu, Peoples R China.; Lu, XF (通讯作者)，Sichuan Univ, West China Hosp, Transplant Ctr, Chengdu, Peoples R China.; Lu, XF (通讯作者)，Sichuan Univ, West China Hosp, NHC Key Lab Transplant Engn & Immunol, Chengdu, Peoples R China.; Lu, XF (通讯作者)，Sichuan Univ, West China Hosp, Inst Syst Genet, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China.; Lu, XF (通讯作者)，Sichuan Univ, West China Hosp, Sichuan Prov Engn Lab Pathol Clin Applicat, Chengdu, Peoples R China.; Zhang, KQ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Ctr Urol & Nephrol, Chongqing, Peoples R China.; Withers, SG (通讯作者)，Univ British Columbia, Dept Chem, Vancouver, BC, Canada.; Withers, SG (通讯作者)，Univ British Columbia, Michael Smith Labs, Vancouver, BC, Canada.; Withers, SG (通讯作者)，Univ British Columbia, Life Sci Ctr, Dept Biochem, Vancouver, BC, Canada.文献类型: Article影响因子: 8.2, JCR分区: Q1, 中信所分区: Q1学院: 附二院摘要：ABO血型不相容的肾移植被广泛用于满足日益增长的器官需求。目前以受者为中心的脱敏方案通过血浆置换清除抗体，增加了感染、围手术期出血事件的风险和医疗成本。在此，我们提出了一种以供者为中心的脱敏方案，在低温灌注期间将A型肾脏转化为酶转化的O型肾脏，以去除肾脏中的A抗原。体外模型结果显示未发生抗体介导的损伤。受此鼓舞，我们将一枚酶转化的O型肾脏移植到一名具有高滴度抗A抗体的O型脑死亡受者体内，未观察到超急性排斥反应。移植后2天内移植物耐受良好，无抗体介导的排斥反应证据。移植后第3天开始出现抗体介导的损伤病变和补体沉积，与A抗原再生同步，随后Banff评分升高，提示免疫介导的反应。单细胞测序证实了适应相关基因的表达升高，表明存在长期耐受的潜力。本研究提供了一种以供者为中心的器官工程策略，并有潜力拓展ABO血型不相容肾移植的应用范围，提高器官分配的公平性和可及性。原文第13条，共79条标题: Perceived organizational Support and Nurses' Caring Behaviors: The Serial Mediating Roles of Perceived Stress and Career Calling期刊: JOURNAL OF NURSING MANAGEMENT作者: Zhu, WF; Wu, Q通讯作者: Wu, Q (通讯作者)，Chongqing Med Univ, Dept Nursing, Affiliated Hosp 1, Chongqing, Peoples R China.文献类型: Article影响因子: 4, JCR分区: Q1, 中信所分区: Q1学院: 护理学院; 附一院摘要：目的：探讨感知组织支持与护士关怀行为之间的关联，并探索感知压力和职业召唤在此关系中的链式中介作用。背景：关怀行为对于高质量的护理服务和患者满意度至关重要。然而，繁重的工作量和心理压力可能会削弱护士的关怀表现。POS作为一种关键的工作资源，可能与关怀行为以及较低的感知压力和更强的内在动机相关。方法：对来自中国重庆市六家三甲医院的648名护士进行横断面调查。使用标准化问卷评估POS、感知压力、CALL和关怀行为。采用结构方程模型结合偏差校正的Bootstrap法检验假设的链式中介模型，并额外进行PROCESS分析以验证稳健性。结果：组织支持与关怀行为呈正相关，并通过感知压力和CALL存在显著的间接关联。该模型解释了关怀行为26%的变异，间接路径约占总效应的26.7%。PROCESS分析结果与假设的链式中介模型一致。结论：POS与护士的关怀行为直接相关，也通过涉及感知压力和CALL的间接路径相关联。这些发现提示，感知压力和CALL可能是连接组织支持与关怀行为的潜在通路。原文第14条，共79条标题: Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD期刊: NATURE COMMUNICATIONS作者: Huang, XJ;Liang, S;Zhao, N; et al.通讯作者: Pan, Q; Chai, J (通讯作者)，Army Med Univ, Cholestat Liver Dis Ctr,Third Mil Med Univ, Inst Digest Dis PLA,Metab Dysfunct Associated Stea, Affiliated Hosp 1,Southwest Hosp,Dept Gastroentero, Chongqing, Peoples R China.; Sun, CZ; Liu, HZ (通讯作者)，Cent South Univ, Xiangya Hosp 3, Dept Emergency, Changsha, Peoples R China.; Hu, XL (通讯作者)，Chongqing Med Univ, Coll Lab Med, Chongqing Med Lab,Microfluid & SPRi Engn Res Ctr, Key Lab Clin Lab Diagnost,Chinese Minist Educ, Chongqing, Peoples R China.; Ouyang, XS (通讯作者)，Yale Univ, Sch Med, Dept Internal Med, Sect Digest Dis, New Haven, CT 06510 USA.文献类型: Article影响因子: 15.7, JCR分区: Q1, 中信所分区: Q2学院: 检验医学院第15条，共79条标题: Fingernail-based metabolomics reveals a stepwise decline in dodecanoic acid associated with Alzheimer's disease progression期刊: JOURNAL OF ADVANCED RESEARCH作者: Zhang, WB;Wu, JN;Deng, ZJ; et al.通讯作者: Lü, Y (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Geriatr, Chongqing, Peoples R China.文献类型: Article影响因子: 13, JCR分区: Q1, 中信所分区: Q2学院: 附一院; 附一院第16条，共79条标题: Modulation of PKCα/ETS1 by klotho restores CYB5R4-dependent mitochondrial function in proximal tubular epithelial cells to attenuate the progression of diabetic kidney disease期刊: CARDIOVASCULAR DIABETOLOGY作者: Gan, C;Zhou, XD;Qiu, L; et al.通讯作者: Yang, HP; Jiang, W; Li, Q (通讯作者)，Chongqing Med Univ, Natl Clin Res Ctr Children & Adolescents Hlth & Di, Minist Educ,Key Lab Child Dev & Disorders,Dept Nep, Chongqing Key Lab Pediat Metab & Inflammatory Dis, Chongqing, Peoples R China.文献类型: Article影响因子: 10.6, JCR分区: Q1, 中信所分区: Q2学院: 附属儿童医院第17条，共79条标题: Dual-Targeted Nanotherapy Restores Redox Homeostasis and Suppresses Uterine Hypercontractility for Effective Preterm Birth Intervention期刊: ADVANCED HEALTHCARE MATERIALS作者: Tang, YG;Cheng, YF;Zhuo, HM; et al.通讯作者: Qi, HB; Cheng, J (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing Key Lab Maternal & Fetal Med, Chongqing, Peoples R China.; Qi, HB (通讯作者)，Chongqing Med Univ, Women & Childrens Hosp, Chongqing, Peoples R China.; Zhang, JX (通讯作者)，Third Mil Med Univ, Army Med Univ, Coll Pharm, Dept Pharmaceut, Chongqing, Peoples R China.; Zhang, JX (通讯作者)，Yu Yue Pathol Sci Res Ctr, Chongqing, Peoples R China.; Zhang, JX (通讯作者)，Third Mil Med Univ, Army Med Univ, State Key Lab Trauma & Chem Poisoning, Chongqing, Peoples R China.文献类型: Article; Early Access影响因子: 9.6, JCR分区: Q1, 中信所分区: Q2学院: 附一院; 附一院, 妇幼保健院第18条，共79条标题: Reinforced Bacterial Cellulose/GelMA-HAMA Bionic Cartilage Hydrogel with Spatiotemporal Delivery of Exosomes and BMSCs for Temporomandibular Joint Disc Regeneration期刊: ADVANCED HEALTHCARE MATERIALS作者: Lu, J;Fan, WZ;Wang, XH; et al.通讯作者: Xu, J (通讯作者)，Chongqing Med Univ, Stomatol Hosp, Chongqing, Peoples R China.; Xu, J (通讯作者)，Chongqing Key Lab Oral Dis, Chongqing, Peoples R China.; Xu, J (通讯作者)，Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing, Peoples R China.; Yang, WH; Cai, KY (通讯作者)，Chongqing Univ, Minist Educ Coll Bioengn, Key Lab Biorheol Sci & Technol, Chongqing, Peoples R China.文献类型: Article; Early Access影响因子: 9.6, JCR分区: Q1, 中信所分区: Q2学院: 附属口腔医院第19条，共79条标题: Cellular-nanoporation boosts high-yield RVG-modified exosomes for multifunctional α-synuclein scavengers against Parkinson's disease期刊: CHINESE CHEMICAL LETTERS作者: Sun, M;Yu, LJ;Bai, L; et al.文献类型: Article影响因子: 8.9, JCR分区: Q1, 中信所分区: Q2学院: 附二院第20条，共79条标题: The battle against skin aging: Advances in natural anti-aging compounds and innovative delivery systems期刊: CHINESE CHEMICAL LETTERS作者: Zhang, SH;Guo, XY;Hao, LH; et al.文献类型: Article影响因子: 8.9, JCR分区: Q1, 中信所分区: Q2学院: 附属大学城医院第21条，共79条标题: Effects of chrononutrition on aging and lifespan期刊: FOOD RESEARCH INTERNATIONAL作者: Wang, YM;Zhang, SY;Xiang, P; et al.通讯作者: Shi, D (通讯作者)，Chongqing Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Chongqing, Peoples R China.文献类型: Review影响因子: 8, JCR分区: Q1, 中信所分区: Q2学院: 公卫学院; 公卫学院第22条，共79条标题: Aging-Associated CCL8+Senescent Macrophages Recruit CCR1+Neutrophils to Promote NETs Formation and Impair Meningeal Lymphatic Drainage期刊: AGING AND DISEASE作者: Yuan, Y;Wang, RL;He, QG; et al.文献类型: Article; Early Access影响因子: 6.9, JCR分区: Q1, 中信所分区: Q2学院: 附二院; 附二院第23条，共79条标题: Niacin promotes motor function recovery after spinal cord injury via Hcar2-dependent microglia immunometabolic regulation期刊: CLINICAL AND TRANSLATIONAL MEDICINE作者: Du, H;Zeng, LN;Liu, C; et al.文献类型: Article影响因子: 6.8, JCR分区: Q1, 中信所分区: Q2学院: 附属儿童医院; 附属儿童医院第24条，共79条标题: Novel Carboline-Based Ferroptosis Inhibitor Ameliorates Acute Liver Injury by Remodeling Phosphatidylcholine期刊: JOURNAL OF MEDICINAL CHEMISTRY作者: Lv, LJ;Li, X;Wan, BW; et al.文献类型: Article; Early Access影响因子: 6.8, JCR分区: Q1, 中信所分区: Q2学院: 药学院; 药学院第25条，共79条标题: Shh-S100A10 axis curbs neuronal PANoptosis after ischemic stroke期刊: NEURAL REGENERATION RESEARCH作者: Wang, L;Tang, H;Wen, J; et al.通讯作者: Yang, Q (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.文献类型: Article影响因子: 6.7, JCR分区: Q1, 中信所分区: Q2学院: 附一院; 附一院第26条，共79条标题: Hierarchical Mesochannel-Confined Nanozyme Reactors Propelling Gold Amplification Immunoassays for Ultrasensitive Point-of-Care Diagnostics期刊: ANALYTICAL CHEMISTRY作者: Cai, H;Ai, ZJ;Gao, X; et al.文献类型: Article; Early Access影响因子: 6.7, JCR分区: Q1, 中信所分区: Q2学院: 检验医学院; 检验医学院第27条，共79条标题: Hepatobiliary transported levofloxacin-loaded nanoparticles for treatment of bacterial biliary infection期刊: COLLOIDS AND SURFACES B-BIOINTERFACES作者: Liao, Y;Zhang, WP;Tang, XY; et al.文献类型: Article影响因子: 5.6, JCR分区: Q1, 中信所分区: Q2学院: 药学院; 药学院第28条，共79条标题: Tectochrysin alleviates Ang II-induced pathological cardiac hypertrophy by binding to STING and inhibiting STING/NFκB-mediated inflammation期刊: FRONTIERS IN PHARMACOLOGY作者: Chen, YH;Li, F;He, Y; et al.通讯作者: Ling, ZY (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Cardiol, Chongqing, Peoples R China.; Ling, ZY (通讯作者)，Cardiovasc Neuromodulat Res & Treatment Ctr, Chongqing, Peoples R China.文献类型: Article影响因子: 4.8, JCR分区: Q1, 中信所分区: Q2学院: 附二院; 附二院第29条，共79条标题: Reported drug spectrum and disproportionality signals for malignant neoplasm progression in FAERS: a real-world pharmacovigilance study期刊: FRONTIERS IN PHARMACOLOGY作者: Liu, YH;Zeng, M;Zhang, MY; et al.通讯作者: Zhang, J (通讯作者)，Natl Clin Res Ctr Children & AdolescentsHealth & D, Chongqing, Peoples R China.; Zhang, J (通讯作者)，Chongqing Med Univ, Childrens Hosp, Dept Surg Oncol, Chongqing, Peoples R China.; Zhang, J (通讯作者)，Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China.; Zhang, J (通讯作者)，Country Chongqing Key Lab Child Rare Dis Infect &, Chongqing, Peoples R China.文献类型: Article影响因子: 4.8, JCR分区: Q1, 中信所分区: Q2学院: 附属儿童医院第30条，共79条标题: Beauvericin promotes autophagy and mitophagy by activating NIPSNAP2期刊: BIOORGANIC CHEMISTRY作者: Zhao, X;Zhang, RH;Ma, YH; et al.文献类型: Article影响因子: 4.7, JCR分区: Q1, 中信所分区: Q2学院: 药学院; 药学院第31条，共79条标题: Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease期刊: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY作者: Xue, LF; Wang, X; Mao, JX通讯作者: Mao, JX (通讯作者)，Chongqing Med & Pharmaceut Coll, Technol Dev Ctr, Chongqing, Peoples R China.; Mao, JX (通讯作者)，Chongqing Med, Pharmaceut Coll, Affiliated Hosp 1, Dept Sci & Educ, Chongqing, Peoples R China.文献类型: Review影响因子: 4.3, JCR分区: Q1, 中信所分区: Q2学院: 附一院第32条，共79条标题: Two cycles of chemotherapy modulate itaconic acid levels via ATF3/TET2/NF-κB pathways in ovarian cancer among Han Chinese women期刊: JOURNAL OF OVARIAN RESEARCH作者: Tang, Y;Wu, J;Wang, Q; et al.通讯作者: Li, J (通讯作者)，North Sichuan Med Coll, Nanchong Cent Hosp, Dept Obstet & Gynecol, Nanchong, Sichuan, Peoples R China.; Han, TL (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing, Peoples R China.文献类型: Article影响因子: 4.2, JCR分区: Q1, 中信所分区: Q2学院: 附二院第33条，共79条标题: The potential role of CD44+monocytes in mediating hyperinflammatory response in bronchopulmonary dysplasia in very premature infants期刊: PEDIATRIC RESEARCH作者: He, Y;Zhou, YZ;Liu, QQ; et al.通讯作者: Wang, NR (通讯作者)，Chongqing Med Univ, Chongqing Hlth Ctr Women & Children, Women & Childrens Hosp, Dept Pediat, Chongqing, Peoples R China.; Wang, NR (通讯作者)，Chongqing Res Ctr Prevent & Control Maternal & Chi, Chongqing, Peoples R China.; Wang, NR (通讯作者)，NHC Key Lab Birth Defects & Reprod Hlth, Chongqing, Peoples R China.文献类型: Article; Early Access影响因子: 3.1, JCR分区: Q1, 中信所分区: Q2学院: 妇幼保健院第34条，共79条标题: Machine learning-based integration of systemic immune-inflammation and nutritional signatures for predicting disease-free survival in upper tract urothelial carcinoma: a multicenter study期刊: FRONTIERS IN IMMUNOLOGY作者: Peng, X;Xiao, BX;Yuan, ZP; et al.通讯作者: Xiao, MZ (通讯作者)，Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, Chongqing, Peoples R China.; Shi, W (通讯作者)，Chongqing Med Univ, Ctr Reprod Med, Chongqing Hlth Ctr Women & Children, Women & Childrens Hosp, Chongqing, Peoples R China.文献类型: Article影响因子: 5.9, JCR分区: Q1, 中信所分区: Q3学院: 妇幼保健院第35条，共79条标题: Case Report: Successful treatment of SAPHO syndrome refractory to adalimumab with upadacitinib期刊: FRONTIERS IN IMMUNOLOGY作者: Du, JW;Li, YS;Geng, SH; et al.通讯作者: Geng, SH (通讯作者)，Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.; Li, C (通讯作者)，Shanghai Guanghua Hosp Integrated Tradit Chinese &, Shanghai, Peoples R China.; Shang, SK (通讯作者)，Chongqing Med Univ, Liangjiang Hosp, Peoples Hosp Chongqing Liangjiang New Area, Dept Tradit Chinese Med Rehabil, Chongqing, Peoples R China.文献类型: Article影响因子: 5.9, JCR分区: Q1, 中信所分区: Q3学院: 附属两江医院; 附属两江医院第36条，共79条标题: TPD52 inhibits aldosterone synthesis through suppression of CAMKK2 signaling期刊: EUROPEAN JOURNAL OF ENDOCRINOLOGY作者: Xie, L;Ma, LQ;Kang, B; et al.文献类型: Article影响因子: 5.2, JCR分区: Q1, 中信所分区: Q3学院: 附一院; 附一院第37条，共79条标题: The impact of daily steps on polycystic ovary syndrome patients期刊: FRONTIERS IN ENDOCRINOLOGY作者: Wang, TM;Zhang, LJ;Ma, LY; et al.通讯作者: Li, C (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Gynecol, Chongqing, Peoples R China.文献类型: Article影响因子: 4.6, JCR分区: Q1, 中信所分区: Q3学院: 附一院; 附一院第38条，共79条标题: A Multi-omics Investigation Identifies TACC3 as a Driver of Immunosuppression in Intrahepatic Cholangiocarcinoma via Activation of the STAT3-PD-L1 Axis期刊: JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY作者: Wang, H;Xu, ZQ;Zhang, ZQ; et al.文献类型: Article影响因子: 4.2, JCR分区: Q1, 中信所分区: Q3学院: 附一院; 附一院第39条，共79条标题: Intradiscal platelet-rich plasma for discogenic low back pain: a prospective cohort study of early clinical outcomes and quantitative MRI findings期刊: SCIENTIFIC REPORTS作者: Pan, XH;Peng, G;Yao, Q; et al.通讯作者: Hao, J (通讯作者)，Chongqing Med Univ, Key Lab Musculoskeletal Regenerat & Translat Med, Affiliated Hosp 1,Dept Orthopaed Surg, Chongqing Municipal Hlth Commiss,Orthopaed Res Lab, Chongqing, Peoples R China.; Jiang, W (通讯作者)，Chongqing Med Univ, Dept Orthopaed, Nanchuan Hosp, Chongqing, Peoples R China.文献类型: Article影响因子: 3.9, JCR分区: Q1, 中信所分区: Q3学院: 附一院; 附一院, 附属南川医院第40条，共79条标题: Multi-omics analysis reveals shared diagnostic and therapeutic targets in endometriosis and recurrent implantation failure期刊: SCIENTIFIC REPORTS作者: Yu, J;Wang, W;Li, Q; et al.通讯作者: Yu, TH (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing, Peoples R China.; Qi, HF (通讯作者)，Chongqing Med Univ, Chongqing Hlth Ctr Women & Children, Women & Childrens Hosp, Chongqing, Peoples R China.文献类型: Article影响因子: 3.9, JCR分区: Q1, 中信所分区: Q3学院: 妇幼保健院第41条，共79条标题: Multi-omics analysis reveals shared diagnostic and therapeutic targets in endometriosis and recurrent implantation failure期刊: SCIENTIFIC REPORTS作者: Yu, J;Wang, W;Li, Q; et al.通讯作者: Yu, TH (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing, Peoples R China.; Qi, HF (通讯作者)，Chongqing Med Univ, Chongqing Hlth Ctr Women & Children, Women & Childrens Hosp, Chongqing, Peoples R China.文献类型: Article影响因子: 3.9, JCR分区: Q1, 中信所分区: Q3学院: 妇幼保健院第42条，共79条标题: Exploring exosome-related genes as candidate biomarkers in primary immune thrombocytopenia through tranomics and preliminary experimental validation期刊: SCIENTIFIC REPORTS作者: Lou, FF;Chen, ZY;Yuan, ZH; et al.文献类型: Article影响因子: 3.9, JCR分区: Q1, 中信所分区: Q3学院: 附一院; 附一院第43条，共79条标题: ROS-NLRP3 participates in the pyroptosis response of excretory-secretory products from protoscoleces of Echinococcus granulosus in hepatocytes期刊: SCIENTIFIC REPORTS作者: Cao, JT;Chen, JQ;Li, HW; et al.文献类型: Article影响因子: 3.9, JCR分区: Q1, 中信所分区: Q3学院: 附属成都二院第44条，共79条标题: Successful treatment of refractory primary follicular mucinosis with Tofacitinib期刊: ANAIS BRASILEIROS DE DERMATOLOGIA作者: Li, YL; Fang, S通讯作者: Fang, S (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Dermatol, Chongqing, Peoples R China.文献类型: Letter影响因子: 3.6, JCR分区: Q1, 中信所分区: Q3学院: 附一院; 附一院第45条，共79条标题: The impact of stress experienced by sexual minorities on depression among chinese men who have sex with men: an analysis of the mediating effects of social support and intimate partner violence期刊: BMC PUBLIC HEALTH作者: Chen, H;Xie, YX;Yang, GH; et al.文献类型: Article影响因子: 3.6, JCR分区: Q1, 中信所分区: Q3学院: 公卫学院; 公卫学院第46条，共79条标题: HIV testing factors among Men Who Have Sex with Men in China: an analysis based on Lasso regression and Bayesian networks期刊: BMC PUBLIC HEALTH作者: Li, JY;Liu, YC;He, W; et al.文献类型: Article影响因子: 3.6, JCR分区: Q1, 中信所分区: Q3学院: 公卫学院; 公卫学院第47条，共79条标题: Construction and Verification of a Risk Prediction Model for Suicidal Ideation in Patients With Bipolar Disorder: A Machine Learning Analysis期刊: ALPHA PSYCHIATRY作者: Luo, X;Lin, XL;Zhao, QH; et al.文献类型: Article影响因子: 3.5, JCR分区: Q1, 中信所分区: Q3学院: 护理学院第48条，共79条标题: Controlling recurrent scabies outbreaks in a geriatric hospital: impact of a prevention bundle and lessons from a breakthrough case期刊: FRONTIERS IN PUBLIC HEALTH作者: Li, LC;Li, RH;Wang, YF; et al.通讯作者: Wang, YF (通讯作者)，Thirteenth Peoples Hosp Chongqing, Dept Infect Control, Chongqing, Peoples R China.; Qian, KL (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Infect Control, Chongqing, Peoples R China.文献类型: Article影响因子: 3.4, JCR分区: Q1, 中信所分区: Q3学院: 附一院第49条，共79条标题: Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves期刊: FRONTIERS IN MEDICINE作者: Zhou, W; Xu, P通讯作者: Xu, P (通讯作者)，Chongqing Med Univ, Univ Town Hosp, Med Sci Res Ctr, Dept Clin Lab, Chongqing, Peoples R China.文献类型: Article影响因子: 3, JCR分区: Q1, 中信所分区: Q3学院: 附属大学城医院; 附属大学城医院第50条，共79条标题: Efficacy of oxycodone in managing visceral pain among women undergoing repeat cesarean section: a randomized controlled trial期刊: FRONTIERS IN MEDICINE作者: Chen, QW;Hu, SS;Liu, J; et al.通讯作者: Li, SQ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Chongqing, Peoples R China.; Chen, MJ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Gynecol & Obstet, Chongqing, Peoples R China.文献类型: Article影响因子: 3, JCR分区: Q1, 中信所分区: Q3学院: 附二院; 附二院第51条，共79条标题: Prediction of skeletal maturity using machine learning based on multiple biological indicators期刊: AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS作者: Guo, M;Daraqel, B;Ai, DQ; et al.文献类型: Article影响因子: 3, JCR分区: Q1, 中信所分区: Q3学院: 附属口腔医院第52条，共79条标题: Smartphone-integrated nanozymes: Classification, catalytic mechanisms, activity regulation, and food analysis applications期刊: SENSORS AND ACTUATORS REPORTS作者: Geng, S; Shuai, MS; Zhang, H文献类型: Article影响因子: 7.6, JCR分区: Q1, 中信所分区: 未找到学院: 附属大足医院第53条，共79条标题: ROS-responsive PLGA microspheres enable localized capsaicin delivery to alleviate rheumatoid arthritis by modulating inflammatory and oxidative microenvironments期刊: COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS作者: Chen, YF;Deng, X;Liu, JC; et al.文献类型: Article影响因子: 5.4, JCR分区: Q2, 中信所分区: Q3学院: 附属儿童医院; 附属儿童医院, 附一院第54条，共79条标题: Development of a predictive model based on clinical indicators for refractory Mycoplasma pneumoniae pneumonia in children: a case-control study期刊: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY作者: Yu, FF; Zhou, Y; Luo, ZX通讯作者: Luo, ZX (通讯作者)，Chongqing Med Univ, Natl Clin Res Ctr Children & AdolescentsHealth & D, Chongqing Key Lab Child Rare Dis Infect & Immun, Minist Educ Key Lab Child Dev & Disorders,Children, Chongqing, Peoples R China.文献类型: Article影响因子: 4.8, JCR分区: Q2, 中信所分区: Q3学院: 重庆医科大学第55条，共79条标题: Dynamic changes in TREX1 and LGALS9 mRNA levels in PBMCs predict HBsAg clearance and treatment responses to Peg-IFN-α therapy in HBeAg-negative chronic hepatitis B patients期刊: VIROLOGY JOURNAL作者: Pang, H;Jiang, JH;Fu, XL; et al.通讯作者: Qin, B (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Chongqing Key Lab Infect Dis & Parasit Dis, Chongqing, Peoples R China.文献类型: Article影响因子: 3.8, JCR分区: Q2, 中信所分区: Q3学院: 附一院; 附一院第56条，共79条标题: The expression profile of type 1 equilibrative nucleoside transporter in aged C57BL/6J mouse brain期刊: ACTA BIOCHIMICA ET BIOPHYSICA SINICA作者: Zhang, XY;Ma, ZT;Jin, YH; et al.文献类型: Article影响因子: 3.4, JCR分区: Q2, 中信所分区: Q3学院: 基础医学院; 基础医学院第57条，共79条标题: Comment on "CAFs-Derived Exosomes Promote Colorectal Cancer Progression Through METTL1-Mediated m7G Modification of SLC1A5 mRNA"期刊: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY作者: Chen, HY; Li, CC通讯作者: Chen, HY (通讯作者)，Chongqing Med Univ, Univ Town Hosp, Dept Gastroenterol, Chongqing, Peoples R China.文献类型: Letter; Early Access影响因子: 3.4, JCR分区: Q2, 中信所分区: Q3学院: 附属大学城医院; 附属大学城医院第58条，共79条标题: Analysis of characteristics of hospitalized patients with chronic insomnia: a single-center retrospective study期刊: FRONTIERS IN PSYCHIATRY作者: Su, H;Bai, JY;Liang, SY; et al.通讯作者: Liang, SY; Wang, ZD (通讯作者)，Fengjie Cty Peoples Hosp Chongqing, Dept Hepatobiliary Surg, Chongqing, Peoples R China.; Liang, SY; Wang, ZD (通讯作者)，Chongqing Med Univ, Fengjie Hosp, Affiliated Hosp 2, Dept Hepatobiliary Surg, Chongqing, Peoples R China.文献类型: Article影响因子: 3.2, JCR分区: Q2, 中信所分区: Q3学院: 附二院第59条，共79条标题: Effect of low-intensity focused ultrasound on hippocampus of alcohol addicted mice: a preliminary study期刊: FRONTIERS IN NEUROSCIENCE作者: Wang, Q;Xiang, XQ;Peng, LJ; et al.通讯作者: Chen, YL (通讯作者)，Chongqing Med Univ, Chongqing Hlth Ctr Women & Children, Dept Pathol, Women & Childrens Hosp, Chongqing, Peoples R China.; Chen, YL (通讯作者)，Natl Hlth Commiss NHC, Key Lab Birth Defects & Reprod Hlth, Chongqing, Peoples R China.; Zou, JZ (通讯作者)，Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, Chongqing, Peoples R China.; Zou, JZ (通讯作者)，Chongqing Med Univ, Chongqing Key Lab Biomed Engn, Chongqing, Peoples R China.文献类型: Article影响因子: 3.2, JCR分区: Q2, 中信所分区: Q3学院: 妇幼保健院第60条，共79条标题: Empagliflozin attenuates elaidic acid-exacerbated cardiac dysfunction post-myocardial infarction via suppression of the NF-κB/NLRP3 pathway期刊: FRONTIERS IN CARDIOVASCULAR MEDICINE作者: Yan, QK;Xiao, J;Yu, CQ; et al.通讯作者: Yin, YH (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Cardiol, Chongqing, Peoples R China.; Yu, CQ (通讯作者)，Chongqing Med Univ, Bishan Hosp, Dept Cardiol, Chongqing, Peoples R China.文献类型: Article影响因子: 2.9, JCR分区: Q2, 中信所分区: Q3学院: 附二院; 附二院, 附属璧山医院第61条，共79条标题: Case Report: Exploring KMT2D mutation in Shone syndrome期刊: FRONTIERS IN CARDIOVASCULAR MEDICINE作者: Cheng, PW;Matthew, C;Wang, GZ; et al.通讯作者: An, Y (通讯作者)，Chongqing Med Univ, Natl Clin Res Ctr Children & Adolescents Hlth & Di, Minist Educ,Key Lab Child Dev & Disorders, Dept Thorac Surg,Childrens Hosp,Chongqing Key Lab, Chongqing, Peoples R China.文献类型: Article影响因子: 2.9, JCR分区: Q2, 中信所分区: Q3学院: 附属儿童医院; 附属儿童医院第62条，共79条标题: Dual trajectories of patient-reported fatigue and sleep disturbance in lung cancer survivors期刊: QUALITY OF LIFE RESEARCH作者: Huang, JJ;Zhang, Y;Dai, YD; et al.文献类型: Article影响因子: 2.7, JCR分区: Q2, 中信所分区: Q3学院: 公卫学院; 公卫学院, 超声医学国重实验室第63条，共79条标题: Association of red blood cell transfusions with bronchopulmonary dysplasia in preterm infants: a retrospective cohort study期刊: BMJ PAEDIATRICS OPEN作者: Peng, XS;Wang, JH;Yang, YQ; et al.通讯作者: Shi, Y (通讯作者)，Chongqing Med Univ, Minist Educ,Key Lab Child Dev & Disorders, Natl Clin Res Ctr Child Hlth & Disorders,Dept Neon, Chongqing Key Lab Child Rare Dis Infect & Immun, Chongqing, Peoples R China.文献类型: Article影响因子: 2.3, JCR分区: Q2, 中信所分区: Q3学院: 附属儿童医院; 附属儿童医院第64条，共79条标题: The geographic patterns of macro- and micronutrient consumption in China: a comparison between urban and rural populations期刊: COGENT FOOD & AGRICULTURE作者: Luo, Y;Chen, J;Xiu, WN; et al.文献类型: Article影响因子: 2.3, JCR分区: Q2, 中信所分区: Q3学院: 附一院; 附一院第65条，共79条标题: The spillover effect of caregiver stigma: A study on the mediating role of depression in patients with epilepsy期刊: EPILEPSY & BEHAVIOR作者: Hu, CM;Shao, F;Song, H; et al.通讯作者: Xiong, F; Xiao, Z (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.文献类型: Article影响因子: 2.3, JCR分区: Q2, 中信所分区: Q3学院: 附一院; 附一院第66条，共79条标题: Longitudinal immune cell dynamics and heterogeneous trajectories in children with scrub typhus: a deive pilot study期刊: BMC PEDIATRICS作者: Hua, YY;Zhang, Y;Zhou, JM; et al.通讯作者: Xu, F (通讯作者)，Chongqing Med Univ, Natl Clin Res Ctr Children & Adolescents Hlth & Di, Key Lab Child Dev & Disorders,Dept Intens Care Uni, Minist Educ,Childrens Hosp,Key Lab Child Dev & Dis, Chongqing, Peoples R China.文献类型: Article影响因子: 2, JCR分区: Q2, 中信所分区: Q3学院: 附属儿童医院第67条，共79条标题: Enteral feeding timing and clinical outcomes in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia: a retrospective cohort study highlighting the challenge of confounding by indication期刊: FRONTIERS IN PEDIATRICS作者: Yue, WH;Liu, GG;Lin, L; et al.通讯作者: Hu, Y (通讯作者)，Chongqing Med Univ, Dept Neonatol, Childrens Hosp, Chongqing, Peoples R China.; Hu, Y (通讯作者)，Natl Clin Res Ctr Children & AdolescentsHealth & D, Chongqing, Peoples R China.; Hu, Y (通讯作者)，Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China.; Hu, Y (通讯作者)，China Int Sci & Technol, Cooperat Base Child Dev & Crit Disorders, Chongqing, Peoples R China.; Hu, Y (通讯作者)，Chongqing Key Lab Struct Birth Defect & Reconstruc, Chongqing, Peoples R China.文献类型: Article影响因子: 2, JCR分区: Q2, 中信所分区: Q3学院: 附属儿童医院; 附属儿童医院第68条，共79条标题: Interpretable two-stage deep learning for pediatric obstructive sleep apnea diagnosis using lateral cephalograms期刊: FRONTIERS IN PEDIATRICS作者: Zhang, JY;Tan, J;Tong, XS; et al.通讯作者: Song, JL; Liu, Y (通讯作者)，Chongqing Med Univ, Affiliated Stomatol Hosp, Chongqing, Peoples R China.; Song, JL; Liu, Y (通讯作者)，Chongqing Key Lab Oral Dis, Chongqing, Peoples R China.; Song, JL; Liu, Y (通讯作者)，Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing, Peoples R China.; Song, JL; Liu, Y (通讯作者)，Chongqing Municipal Hlth Commiss, Key Lab Oral Biomed Engn, Chongqing, Peoples R China.; Liu, Y (通讯作者)，Western Inst Digital Intelligent Med, Chongqing, Peoples R China.文献类型: Article影响因子: 2, JCR分区: Q2, 中信所分区: Q3学院: 附属口腔医院第69条，共79条标题: Diagnostic and prognostic role of GPX1 in NK/T cell lymphoma期刊: TUMORI JOURNAL作者: Tang, W;Zhao, M;He, J; et al.文献类型: Article; Early Access影响因子: 3.1, JCR分区: Q2, 中信所分区: Q4学院: 基础医学院第70条，共79条标题: GJA1R148Q Variant Independently Cause Spastic Paraparesis or Interact with Other Pathogenic Variants?期刊: MOVEMENT DISORDERS CLINICAL PRACTICE作者: Shi, YQ; Liu, TF; Zhong, M通讯作者: Zhong, M (通讯作者)，Chongqing Med Univ, Natl Clin Res Ctr Children & Adolescents Hlth & Di, Dept Rehabil,Childrens Hosp, Minist Educ,Key Lab Child Dev & Disorders, Chongqing, Peoples R China.文献类型: Letter; Early Access影响因子: 2.7, JCR分区: Q2, 中信所分区: Q4学院: 附属儿童医院第71条，共79条标题: Relationship between hypertension during dialysis and body composition in non-overweight/overweight obese patients期刊: PLOS ONE作者: Chen, JY;Lu, XQ;Yang, JR; et al.通讯作者: Wang, YY (通讯作者)，Chongqing Med Univ, Affiliated Hosp 3, Dept Nephrol, FangDa Hosp, Chongqing, Peoples R China.文献类型: Article影响因子: 2.6, JCR分区: Q2, 中信所分区: Q4学院: 附三院; 附三院第72条，共79条标题: Left atrial reservoir strain and the left atrioventricular coupling index in association with left ventricular diastolic dysfunction in non-dialysis chronic kidney disease with preserved ejection fraction: a cross-sectional study期刊: BMC CARDIOVASCULAR DISORDERS作者: Zhang, BL;Dong, Y;Li, YM; et al.文献类型: Article影响因子: 2.3, JCR分区: Q2, 中信所分区: Q4学院: 附属巴南医院第73条，共79条标题: Four-dimensional flow MRI-based prediction of minimal hepatic encephalopathy in patients with liver cirrhosis期刊: ABDOMINAL RADIOLOGY作者: Li, X;Li, X;Zheng, Y; et al.通讯作者: Guo, DJ; Zhou, J (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Radiol, Chongqing, Peoples R China.文献类型: Article; Early Access影响因子: 2.2, JCR分区: Q2, 中信所分区: Q4学院: 附二院; 附二院第74条，共79条标题: Epidemiology and disparities of mortality in comorbid cardiovascular disease and osteoporosis: A 25-year nationwide study in the United States期刊: JOURNAL OF INVESTIGATIVE MEDICINE作者: Tu, JY; Yi, TP; Tu, MQ通讯作者: Tu, MQ (通讯作者)，Second Peoples Hosp Yubei Dist, Endocrinol Dept, Chongqing, Peoples R China.文献类型: Article; Early Access影响因子: 2, JCR分区: Q2, 中信所分区: Q4学院: 附一院第75条，共79条标题: Hyperglycemia-driven metabolic memory signaling destabilizes METTL1 to trigger inflammatory hypertrophy and fibrosis in diabetic cardiomyopathy期刊: ACTA DIABETOLOGICA作者: Yuan, YR;Zhang, A;Jiang, Y; et al.通讯作者: Zhu, H (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Cardiol, Fucheng Rd, Beijing, Peoples R China.; Zeng, Y (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Pharm, Beijing, Peoples R China.; Shi, HS (通讯作者)，Shandong Univ Tradit Chinese Med, Jinan, Peoples R China.文献类型: Article; Early Access影响因子: 2.9, JCR分区: Q3, 中信所分区: Q4学院: 附一院第76条，共79条标题: Identification of Key Genes Related to SUMOylation and Potassium Channels and Their Mechanism of Influence on Pulmonary Arterial Hypertension期刊: BIOCHEMICAL GENETICS作者: Gao, LY;Huang, W;Wang, QQ; et al.文献类型: Article; Early Access影响因子: 1.6, JCR分区: Q3, 中信所分区: Q4学院: 附一院; 附一院第77条，共79条标题: The evidence for the use of peripheral blood indices in the diagnosis of breast cancer期刊: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH作者: Zhou, ZH;Zhou, Y;Liang, L; et al.文献类型: Article影响因子: 1.5, JCR分区: Q3, 中信所分区: Q4学院: 附一院; 附一院第78条，共79条标题: Comparison of Contrast-Enhanced Ultrasound and Enhanced Magnetic Resonance Imaging in Assessing the Depth of Invasion in Bladder Urothelial Carcinoma期刊: UROLOGIA INTERNATIONALIS作者: Dou, YQ;Chen, XY;Guo, JW; et al.通讯作者: Zhao, T (通讯作者)，Chongqing Med Univ, Dept Urol, Yongchuan Hosp, Chongqing, Peoples R China.文献类型: Article; Early Access影响因子: 1.3, JCR分区: Q3, 中信所分区: Q4学院: 附属永川医院; 附属永川医院第79条，共79条标题: Electrochemical Aptasensor Based on Metal-Organic Framework-derived Bimetallic Materials as Signal Amplifying Elements for Sensitive Detection of Human Epididymis Protein 4期刊: CHINESE JOURNAL OF ANALYTICAL CHEMISTRY作者: Zhu, GJ;Wu, YJ;Hu, RQ; et al.文献类型: Article影响因子: 1.3, JCR分区: Q4, 中信所分区: Q4学院: 药学院*蓝色字体部分为中信所分区Q1期刊论文，文献类型为Article和Review。文中中文摘要由 AI 辅助翻译，准确含义以英文原文为准。文稿：罗丽排版：唐浩睿编辑|初审：李铭复审：欧荣终审：陈朝琴END返回搜狐，查看更多

100 项与盐酸羟考酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00847	盐酸羟考酮	N02AA05	DBSALT000277

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癌症疼痛	日本	Shionogi Pharma Co., Ltd.	2012-05-01
急性疼痛	中国	Bard Pharmaceuticals Ltd.	2004-01-21
慢性疼痛	中国	Bard Pharmaceuticals Ltd.	2004-01-21
疼痛	美国	Roxane Laboratories, Inc.	1998-10-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腰痛	临床3期	美国	Egalet Ltd.	2016-03-01
脊椎骨关节炎	临床3期	美国	Purdue Pharma LP	2004-04-01
镇痛	临床1期	美国	Purdue Pharma LP	2010-07-01
镇痛	临床1期	澳大利亚	Purdue Pharma LP	2010-07-01
镇痛	临床1期	芬兰	Purdue Pharma LP	2010-07-01
镇痛	临床1期	新西兰	Purdue Pharma LP	2010-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07223450 (CTgov)	临床1期	-	8	oxycodone (Group: Oral)	鹹繭鬱膚願窪鏇築糧壓(糧繭憲鑰範築簾衊顧壓) = 鹹選網膚構廠願鹽鹹鑰獵獵範艱鹽遞齋鑰繭廠 (簾齋憲築醖窪積窪遞壓, 1954.6) 更多	-	2026-05-06
				oxycodone (Group Intranasal)	鹹繭鬱膚願窪鏇築糧壓(糧繭憲鑰範築簾衊顧壓) = 遞積積顧鑰醖糧餘範醖獵獵範艱鹽遞齋鑰繭廠 (簾齋憲築醖窪積窪遞壓, 1824.8) 更多
NCT06041425 (Pubmed \| J Vasc Interv Radiol)	临床4期	疼痛	40	Oxycodone	鬱餘蓋壓醖齋鬱壓鹽獵(壓鬱齋齋醖繭選鬱膚顧) = Adverse event rates were comparable. 鹽醖繭糧鬱夢顧網鬱鏇 (蓋膚衊廠夢淵衊鑰膚窪 )	积极	2026-05-01
				Sufentanil
NCT03574792 (CTgov)	临床2期	疼痛 \| 头颈部皮肤鳞状细胞癌	62	Quality-of-Life Assessment+Oxycodone+Methadone+Gabapentin (Arm I (Gabapentin, Methadone, Oxycodone))	觸積餘壓繭醖積鏇襯製(鑰範淵憲遞窪憲範簾糧) = 構壓築壓艱簾糧選鏇夢壓選廠構鑰蓋鹹觸觸遞 (壓廠蓋壓鏇壓憲製襯淵, 10) 更多	-	2026-04-16
				Quality-of-Life Assessment+Oxycodone+Methadone+Venlafaxine+Gabapentin (Arm II (Gabapentin, Methadone, Oxycodone, Venlafaxine))	觸積餘壓繭醖積鏇襯製(鑰範淵憲遞窪憲範簾糧) = 簾夢構鏇鹹願憲鑰壓餘壓選廠構鑰蓋鹹觸觸遞 (壓廠蓋壓鏇壓憲製襯淵, 17) 更多
NCT05974501 (CTgov)	临床4期	关节置换术并发症 \| 膝关节炎 \| 术后疼痛	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	顧網糧構膚糧觸鹹選餘(觸鬱憲廠構鹹衊蓋鬱糧) = 願構襯衊構夢壓窪鬱糧鏇顧餘簾遞襯蓋廠積範 (襯願鏇鏇鏇鹹襯鏇膚廠, 獵鬱齋廠選鑰構襯獵蓋 ~ 築鏇醖鬱獵壓衊夢鬱膚) 更多	-	2025-02-12
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	顧網糧構膚糧觸鹹選餘(觸鬱憲廠構鹹衊蓋鬱糧) = 獵襯齋鏇製膚觸廠構範鏇顧餘簾遞襯蓋廠積範 (襯願鏇鏇鏇鹹襯鏇膚廠, 願襯衊遞鹹蓋夢鬱衊膚 ~ 構願齋鑰糧壓廠艱餘襯) 更多
NCT01458015 (CTgov)	临床4期	神经痛	3	oxycodone+tapentadol (Oxycodone)	繭鏇製範築選醖範淵壓(選顧壓繭鏇艱憲壓繭選) = 壓選衊醖淵獵製鹹繭餘網網餘積築糧觸憲齋膚 (積遞鹹選鬱鹽鏇鏇鏇糧, 壓鏇顧襯鬱繭選簾糧膚 ~ 鏇艱築蓋餘鹽積憲窪構) 更多	-	2024-12-17
				oxycodone+tapentadol (Tapentadol)	繭鏇製範築選醖範淵壓(選顧壓繭鏇艱憲壓繭選) = 齋觸窪積簾壓齋鹹鑰遞網網餘積築糧觸憲齋膚 (積遞鹹選鬱鹽鏇鏇鏇糧, 餘餘獵膚鑰鹽積簾淵網 ~ 範壓獵窪願糧顧衊淵鹽) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	觸顧膚窪鏇遞鹹鬱願願(鑰糧淵窪廠壓餘膚觸艱) = 淵鏇鏇餘願構糧鏇鏇範憲鹹鹹選夢鬱積築願齋 (築製壓蓋鹹構範憲鹽夢, 齋製顧獵鑰廠餘積醖鑰 ~ 繭積糧衊壓選願鏇醖鹹) 更多	-	2024-09-19
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	觸顧膚窪鏇遞鹹鬱願願(鑰糧淵窪廠壓餘膚觸艱) = 廠鏇蓋繭遞淵遞獵糧淵憲鹹鹹選夢鬱積築願齋 (築製壓蓋鹹構範憲鹽夢, 鹽襯淵醖夢築簾繭鬱積 ~ 鬱淵觸獵鏇鏇壓壓窪顧) 更多
NCT04791761 (CTgov)	临床1/2期	术后疼痛	73	Opioid disposal education+Acetaminophen+Oxycodone+Ibuprofen (Opioid Pain Control)	膚製窪醖鑰繭憲憲獵夢(築構壓餘鬱觸簾憲遞糧) = 獵範窪醖窪夢觸繭壓鏇餘餘願蓋築淵鬱製糧繭 (鬱糧製廠壓積襯積構鏇, 鹹構簾壓醖淵鹹壓醖衊 ~ 膚獵餘糧膚憲簾築鏇網) 更多	-	2024-08-16
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	膚製窪醖鑰繭憲憲獵夢(築構壓餘鬱觸簾憲遞糧) = 構鏇鑰憲糧選顧遞構艱餘餘願蓋築淵鬱製糧繭 (鬱糧製廠壓積襯積構鏇, 觸膚選獵淵糧壓蓋鹽齋 ~ 顧鏇簾範範蓋鏇糧簾廠) 更多
NCT04015908 (CTgov)	临床4期	-	100	Pregabalin+Acetaminophen+Oxycodone+celecoxib (Multi-modal)	憲範網願醖鏇鏇鏇願範(醖糧鹽襯齋醖構壓遞醖) = 艱構繭壓鏇襯廠壓網鏇齋遞艱鬱築鏇膚鹽鑰願 (積鬱醖鹹窪淵繭壓願範, 獵獵積壓願淵積鑰壓廠 ~ 遞製醖衊簾醖襯顧顧鹽) 更多	-	2024-07-08
				Percocet (Control)	憲範網願醖鏇鏇鏇願範(醖糧鹽襯齋醖構壓遞醖) = 鏇鏇繭膚構獵蓋襯繭網齋遞艱鬱築鏇膚鹽鑰願 (積鬱醖鹹窪淵繭壓願範, 觸膚糧積膚憲憲鬱觸積 ~ 鹹糧鑰構選獵夢憲網憲) 更多
NCT03612713 (CTgov)	早期临床1期	药物滥用	20	Oxycodone (Oxycodone Run)	積構齋齋繭繭鬱獵襯築(獵膚窪衊鏇遞鹹築觸鹹) = 夢鬱鑰獵衊鏇製築製淵鏇繭鹽構鏇觸衊積願簾 (壓憲顧願膚齋觸簾積鏇, 1.37) 更多	-	2024-03-08
				placebo (Placebo Run)	積構齋齋繭繭鬱獵襯築(獵膚窪衊鏇遞鹹築觸鹹) = 齋夢築糧選築積鏇範醖鏇繭鹽構鏇觸衊積願簾 (壓憲顧願膚齋觸簾積鏇, 2.46) 更多
NCT04122443 (CTgov)	临床4期	肌肉骨骼疼痛	393	Acetaminophen+Ibuprofen (Ibuprofen and Then Acetaminophen (Stage 2))	廠網艱膚糧築選襯顧鏇(廠餘襯繭顧醖繭糧膚願) = 齋壓鬱網廠衊顧鑰艱衊製鬱鹽窪襯蓋顧觸積簾 (選構鏇淵遞築繭壓積遞, 2.4) 更多	-	2024-02-28
				Acetaminophen+Oxycodone+Ibuprofen (Ibuprofen and Then Oxycodone/Acetaminophen (Stage 2))	廠網艱膚糧築選襯顧鏇(廠餘襯繭顧醖繭糧膚願) = 衊鹹淵鬱願艱窪鑰顧獵製鬱鹽窪襯蓋顧觸積簾 (選構鏇淵遞築繭壓積遞, 2.6) 更多